Get the Stockscreener App
4.37
0.46%
-0.02
After Hours:
4.36
-0.010
-0.23%
Evoke Pharma Inc stock is traded at $4.37, with a volume of 13,428.
It is down -0.46% in the last 24 hours and down -17.55% over the past month.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
See More
Previous Close:
$4.39
Open:
$4.35
24h Volume:
13,428
Relative Volume:
0.04
Market Cap:
$6.49M
Revenue:
$5.18M
Net Income/Loss:
$-7.79M
P/E Ratio:
-1.8517
EPS:
-2.36
Net Cash Flow:
$-4.99M
1W Performance:
-4.17%
1M Performance:
-17.55%
6M Performance:
-15.70%
1Y Performance:
-71.99%
1-Day Range:
$4.31
$4.45
1-Week Range:
$4.26
$4.61
52-Week Range:
$3.54
$17.40
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858-345-1494
Address
420 STEVENS AVENUE, SOLANA BEACH, CA
Compare EVOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
4.37 | 6.49M | 5.18M | -7.79M | -4.99M | -2.36 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Oct-19-17 | Resumed | FBR & Co. | Buy |
| Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
| Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
| Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
| Jul-19-16 | Reiterated | FBR Capital | Outperform |
| Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
| Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Mar-16-16 | Initiated | Northland Capital | Outperform |
| Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
| Feb-17-16 | Resumed | FBR Capital | Outperform |
| Dec-03-14 | Reiterated | MLV & Co | Buy |
| Nov-07-14 | Initiated | MLV & Co | Buy |
| Apr-22-14 | Initiated | Laidlaw | Buy |
| Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Mesenchymal Stem Cells (MSC) Market Set to Surpass USD 9.72 - GlobeNewswire
Diabetic Gastroparesis Pipeline 2024: Clinical Trials - openPR
EVOK (Evoke Pharma) Total Assets : $14.15 Mil (As of Sep. 2024) - GuruFocus.com
Diabetic Gastroparesis Treatment Market: Global Size, Share, - openPR
Altium Capital Management LP Increases Stake in Evoke Pharma Inc - GuruFocus.com
Canopy Growth (CGC) Stock Dives Amid Financial Struggles and Ind - GuruFocus.com
CRON Experiences Significant Stock Dip Amid Market Volatility - GuruFocus.com
Nasal Drug Delivery Technology Market Breakthrough in Patient Care, Projected Market Growth to USD 7.8 Billion by 2031Market Research Intellect - The Malaysian Reserve
By popular demand: SiGMA Europe launches fourth shed - GlobeNewswire Inc.
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com - Defense World
Evoke Pharma Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Evoke Pharma earnings missed by $0.95, revenue fell short of estimates - Investing.com UK
(EVOK) Trading Advice - Stock Traders Daily
BlackLine Announces the Planned Retirement of Chief Financial Officer and Names Successor - The Manila Times
Evoke Pharma Reports Q3 2024 Financial Results - TipRanks
Canopy Growth (CGC) Stock Surges 5.2% Amid Industry Movement - GuruFocus.com
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results - The Manila Times
Nantahala Capital Management's Strategic Acquisition in Evoke Ph - GuruFocus.com
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Ironwood Pharmaceuticals (IRWD) Sees Stock Surge Amid Positive A - GuruFocus.com
Is Abbott Laboratories (ABT) the Best Pharma Stock to Buy Right Now? - Yahoo Canada Finance
Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit - Yahoo Finance
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
Global Digestive Health Market Size, Share And Growth Analysis For 2024-2033 - EIN News
Canopy Growth Corporation (CGC) Stock Price, News, Quote & History - Yahoo Finance
Evoke Pharma (FRA:EV0) Enterprise Value : €1.02 Mil (As of Nov. 01, 2024) - GuruFocus.com
Gastroparesis Treatment Market Top Trends and Growth Analysis: - openPR
When Will Evoke Pharma, Inc. (NASDAQ:EVOK) Become Profitable? - Simply Wall St
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Five things for pharma marketers to know for Tuesday morning - MM+M Online
S&P 500 Moves Higher; Philips Shares Plunge After Q3 Earnings - MSN
Evoke Pharma holds Buy rating with $18 target from Laidlaw - Investing.com
Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart
EVOK Stock Earnings: Evoke Pharma Misses EPS, Misses Revenue for Q2 2024 - MSN
Evoke Pharma Shares Soar on Positive Data for Gimoti Nasal Treatment in Diabetic Gastroparesis - Yahoo Finance
What made Evoke Pharma stock more than double on Monday? - Invezz
Crude Oil Tumbles Over 5%; Autonomix Medical Shares Spike Higher - Benzinga
Evoke Pharma Shares Rise 70% on Gimoti Data in GLP-1 Users - MarketWatch
Evoke stock rockets 90% on study of Gimoti in GLP-1 users (NASDAQ:EVOK) - Seeking Alpha
Dow Jumps Over 300 Points; ON Semiconductor Earnings Top ViewsHealthcare Triangle (NASDAQ:HCTI) - Benzinga
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Evoke Pharma Stock Is Soaring Monday: What's Going On? - Benzinga
Evoke Pharma reports significant benefits of GIMOTI in DGP study - Investing.com India
Evoke Pharma & EVERSANA Announce Statistically Significant - GlobeNewswire
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI® - StockTitan
Evoke Pharma Inc Stock (EVOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):